financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis
Dec 11, 2024 8:25 AM

11:02 AM EST, 12/11/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.

The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.

Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.

Shares of Enlivex Therapeutics ( ENLV ) were down 1.6% in recent trading.

Price: 1.23, Change: -0.02, Percent Change: -1.60

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EXPLAINER-Why does the port of Fujairah matter to the oil market?
EXPLAINER-Why does the port of Fujairah matter to the oil market?
Mar 16, 2026
(Adds March 16 Fujairah attack) LONDON, March 16 (Reuters) - Oil loadings at the United Arab Emirates' Fujairah port, a major global hub for refuelling ships as well as crude and fuel exports, have been disrupted after multiple drone attacks in recent days. WHY DOES FUJAIRAH MATTER GLOBALLY? Fujairah exported more than 1.7 million barrels per day of crude oil...
 Altus Group Commencing Substantial Issuer Bid
Altus Group Commencing Substantial Issuer Bid
Mar 16, 2026
08:39 AM EDT, 03/16/2026 (MT Newswires) -- Altus Group ( ASGTF ) , a provider of commercial real estate intelligence, further to its previously announced capital return objectives, announced Monday the commencement of a substantial issuer bid that will see it offer to purchase for cancellation up to C$200 million of its common shares. A statement noted the SIB commences...
 Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/TIAA-CREF Investment Management, LLC/Teachers Advisors, LLC (b) Owner or controller of interests and short positions disclosed,...
 United Therapeutics Insider Sold Shares Worth $5,109,148, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $5,109,148, According to a Recent SEC Filing
Mar 16, 2026
08:40 AM EDT, 03/16/2026 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on March 12, 2026, sold 9,500 shares in United Therapeutics ( UTHR ) for $5,109,148. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 639,489 common shares of the company, with 130 shares held directly and 639,359 controlled...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved